Pure Life Healthcare Management

Pure Life Healthcare Management: Full-spectrum Strategy for PTSD Care


Pure Life Healthcare Management aims to change the healthcare landscape for people suffering from post-traumatic stress disorder (PTSD) with more than 20 services to support PTSD and trauma, creating a wrap-around healthcare ecosystem that provides patients with everything they need to heal.

The company is backed by an experienced team with a deep understanding of issues surrounding mental health. It is also structured to leverage its own value chain, which includes wrap-around care clinics, occupational therapy, alternative medical treatments, pharmacies and partnerships with organizations such as Heroes Haven Society.

Purelife Key Services and Partnerships​Key Services and Partnerships

Pure Life Healthcare Management’s wraparound approach to healthcare will provide support throughout the entire healing process, from counseling and medical testing to dentistry and physiotherapy. The majority of clients are expected to require only a light to medium touch, with one to six visits per month. However, Pure Life also expects a minority of highly complex cases which will require up to $100,000 annually per client with 10 to 20 visits per month.

Company Highlights

  • Over 1.3 million Canadians currently struggle with PTSD and trauma, a population largely underserved by the country's mental health services.
  • Canada is implementing a National Strategy for PTSD focused on prevention, early treatment and intervention, increasing funding for mental health services and looking for partners.
  • Pure Life Healthcare Management is strategically positioned to be among these partners.
  • Pure Life Healthcare Management offers more than 20 services to support PTSD and trauma, creating a wrap-around healthcare ecosystem that provides patients with everything they need to heal.
  • The company is backed by an experienced leadership team and a business structure designed to maximize the value chain, which includes:
    • Wrap-around care clinics
    • Pharmacies
    • Alternative medicines
    • Occupational therapies
    • Partnerships
    • Joint ventures
    • Real estate and commercial holdings
  • One of Pure Life Healthcare Management's most prominent partnerships is with the non-profit Heroes Haven Society, which provides free testing and support for individuals suffering from trauma.
  • The majority of Pure Life Healthcare Management’s revenue will stem from government and insurance benefits.
  • Pure Life Healthcare Management has begun with a virtual model, and is preparing to acquire its first physical location in 2023. The virtual presence will be maintained to serve the remote and restricted community, and as a way to measure patient concentration by area, driving physical location demand and profitability from day one. This strategy is expected to deliver the following revenues:
    • Phase 1 (2023): $690,000 with 14,400 clients and one physical location.
    • Phase 2 (2024): $29.90 million with 27,000 clients and two physical locations.
    • Phase 3 (2025): $90.85 million with 40,000 clients and four physical locations.

This Pure Life Healthcare Management profile is part of a paid investor education campaign.*

Click here to connect with Pure Life Healthcare Management to receive an Investor Presentation

Metals.io

Metals.io Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Metals.io

Metals.io

Tokenized commodities on Tezos: uranium, gold, strategic metals and more

Tokenized commodities on Tezos: uranium, gold, strategic metals and more Keep Reading...
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components... Keep Reading...
US Food and Drug Administration website on a phone screen.

Eli Lilly Cancer Drug Wins FDA Breakthrough Therapy Status

The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Eli Lilly and Company's (NYSE:LLY) experimental drug olomorasib as a standalone treatment for patients with advanced pancreatic cancer and a KRAS G12C mutation who have received at least one systemic... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover, develop and commercialize major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial... Keep Reading...
Stethoscope rests on stacks of US money over a bright blue background.

Eli Lilly to Buy Psychedelics Firm AtaiBeckley for US$2.8 Billion

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is pushing further into the psychedelic drug market with a US$2.8 billion buyout of clinical-stage developer AtaiBeckley (NASDAQ:ATAI). The crown jewel of the deal is BPL-003, a clinic-administered nasal spray derived from dimethyltryptamine... Keep Reading...
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell's pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026" briacell... Keep Reading...
Metals.io

Metals.io Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News